{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:45:26Z","timestamp":1772664326143,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0239328","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T17:33:25Z","timestamp":1600882405000},"page":"e0239328","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates\/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-8149","authenticated-orcid":true,"given":"Sabira","family":"Tahseen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal Masood","family":"Khanzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alamdar Hussain","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Qadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Ghazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurangzaib Quadir","family":"Baloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tehmina","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"9","key":"pone.0239328.ref001","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"DA Mitchison","year":"2000","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"pone.0239328.ref002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5588\/ijtld.16.0716","article-title":"Isoniazid-resistant tuberculosis: a cause for concern?","author":"HR Stagg","year":"2017","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"pone.0239328.ref003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","author":"Deun A Van","year":"2018","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"pone.0239328.ref004","author":"World Health Organization","year":"2017","journal-title":"Guidelines for treatment of drug-susceptible tuberculsois and patient care"},{"key":"pone.0239328.ref005","author":"World Health Organization","year":"2019","journal-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment"},{"key":"pone.0239328.ref006","author":"World Health Organization","year":"2018","journal-title":"Latent tuberculosis infection\u2014updated and consolidated guidelines for pro- grammatic management"},{"key":"pone.0239328.ref007","author":"World Health Organization","year":"2019","journal-title":"Global Tuberculosis Report"},{"issue":"1","key":"pone.0239328.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-21378-x","article-title":"Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations","volume":"8","author":"P Lempens","year":"2018","journal-title":"Scientific Reports"},{"issue":"7","key":"pone.0239328.ref009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/AAC.00092-19","article-title":"Isoniazid resistance in mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping mic distributions with different underlying resistance mechanisms","volume":"63","author":"A Ghodousi","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"pone.0239328.ref010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0037956","article-title":"Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis","volume":"7","author":"R Dantes","year":"2012","journal-title":"PLoS ONE"},{"key":"pone.0239328.ref011","doi-asserted-by":"crossref","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"M Seifert","year":"2015","journal-title":"PloS ONE"},{"issue":"1","key":"pone.0239328.ref012","first-page":"e1003008","article-title":"Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data","volume":"17","author":"AS Dean","journal-title":"PLoS Medicine. 2020"},{"issue":"2","key":"pone.0239328.ref013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Winters N, Benedetti A, Soolingen D Van, Menzies D.Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"M Gegi","year":"2017","journal-title":"The Lancet Infectious Diseases"},{"issue":"4","key":"pone.0239328.ref014","doi-asserted-by":"crossref","DOI":"10.5588\/ijtld.15.0645","article-title":"Use of Xpert\u00ae MTB\/RIF assay in the first national antituberculosis drug resistance survey in Pakistan","volume":"20","author":"S Tahseen","year":"2016","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"10","key":"pone.0239328.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"M Zignol","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"key":"pone.0239328.ref016","unstructured":"Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018 (WHO\/CDS\/TB\/2018.5). License: CC BY-NC-SA 3.0 IGO"},{"key":"pone.0239328.ref017","unstructured":"Global Laboratory inititiative(GLI), StopTB partnership, Mycobacteriology laboratory manual 1st edition. 2014; http:\/\/www.who.int\/tb\/laboratory\/mycobacteriology-laboratory-manual.pdf accessed on 1st July 2020."},{"key":"pone.0239328.ref018","unstructured":"Global Laboratory inititiative(GLI), StopTB partnership, Line probe assays for drug resistant tuberculosis detection Interpretation and reporting guide for laboratory staff and clinicians http:\/\/www.stoptb.org\/wg\/gli\/assets\/documents\/LPA_test_web_ready.pdf, accessed on 1st July 2020."},{"issue":"8","key":"pone.0239328.ref019","doi-asserted-by":"crossref","first-page":"900","DOI":"10.5588\/ijtld.18.0531","article-title":"Primary drug resistance in extra-pulmonary tuberculosis: a hospital-based prospective study from Pakistan","volume":"23","author":"S Tahseen","year":"2019","journal-title":"INT J TUBERC LUNG DIS"},{"issue":"4","key":"pone.0239328.ref020","first-page":"e303","article-title":"International Journal of Infectious Diseases Characterizing Mycobacterium tuberculosis isolates from Karachi, Pakistan: drug resistance and genotypes","volume":"16","author":"A Ayaz","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"pone.0239328.ref021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5588\/ijtld.16.0444","article-title":"Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan","author":"A Javaid","year":"2017","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"11","key":"pone.0239328.ref022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1371\/journal.pone.0050551","article-title":"High Isoniazid Resistance Rates in Rifampicin Susceptible Mycobacterium tuberculosis Pulmonary Isolates from Pakistan","volume":"7","author":"N Fasih","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"pone.0239328.ref023","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1542\/peds.2015-0172","article-title":"Global and regional burden of isoniazid-resistant tuberculosis","volume":"136","author":"CM Yuen","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"pone.0239328.ref024","first-page":"326","article-title":"Prevalence of primary multidrug resistance to anti-tuberculosis drugs in Pakistan","volume":"12","author":"A Javaid","year":"2008","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"8","key":"pone.0239328.ref025","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.00553-13","article-title":"Rifampin drug resistance tests for tuberculosis: challenging the gold standard","volume":"51","author":"A Van Deun","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"7","key":"pone.0239328.ref026","doi-asserted-by":"crossref","first-page":"721","DOI":"10.5588\/ijtld.17.0140","article-title":"Deun A Van, Kranzer K. How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?","volume":"21","author":"H Hoffmann","year":"2017","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"5","key":"pone.0239328.ref027","doi-asserted-by":"crossref","first-page":"e0233500","DOI":"10.1371\/journal.pone.0233500","article-title":"The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance","volume":"15","author":"A Van Deun","year":"2020","journal-title":"PLoS ONE"},{"key":"pone.0239328.ref028","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S1473-3099(18)30496-1","article-title":"Outbreak of multidrug- resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study","volume":"18","author":"NA Makhado","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pone.0239328.ref029","article-title":"Xpert MTB \/ RIF-detected Rifampicin Resistance is a Sub-Optimal Surrogate for Multidrug Resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications","author":"JB Nachega","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"pone.0239328.ref030","doi-asserted-by":"crossref","first-page":"e0221485","DOI":"10.1371\/journal.pone.0221485","article-title":"Evaluation of GenoType MTBDRplus for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Karachi, Pakistan","volume":"14","author":"S Siddiqui","year":"2019","journal-title":"PLoS ONE"},{"issue":"12","key":"pone.0239328.ref031","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/infdis\/jiaa042","article-title":"Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion","volume":"221","author":"EV Kurbatova","year":"2020","journal-title":"JID"},{"issue":"3","key":"pone.0239328.ref032","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ng.3767","article-title":"Genomic analysis of globally diverse Mycobacterium Tuberculosis strains provides insights into the emergence and spread of multidrug resistance","volume":"49","author":"AL Manson","year":"2017","journal-title":"Nat Genet"},{"issue":"8","key":"pone.0239328.ref033","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00077-13","article-title":"Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes","volume":"57","author":"MN Huyen","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"pone.0239328.ref034","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/cir406","article-title":"Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa","volume":"53","author":"KR Jacobson","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0239328.ref035","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"SK Katiyar","year":"2008","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"pone.0239328.ref036","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/cid\/ciz039","article-title":"Improved outcomes with high-dose isoniazid in multidrugresistant tuberculosis treatment in Haiti","volume":"69","author":"KF Walsh","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0239328.ref037","article-title":"A5312 Study Team. Early bactericidal activity of different isoniazid doses for drug resistant TB (INHindsight): a randomized open-label clinical trial","author":"KE Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0239328.ref038","article-title":"Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005\u20132009 [letter]","author":"K Jabeen","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"pone.0239328.ref039","volume-title":"The end TB strategy, Global strategy and targets for tuberculosis prevention, care and control after 2015","author":"World Health Organization","year":"2015"},{"key":"pone.0239328.ref040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/JCM.01771-16","article-title":"Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use","volume":"55","author":"S Chakravorty","year":"2017","journal-title":"J Clin Microbiol"},{"key":"pone.0239328.ref041","unstructured":"FIND press release, New rapid molecular test for tuberculosis can simultaneously detect resistance to first- and second-line drugs 16 July 2020, Available from https:\/\/www.finddx.org\/wp-content\/uploads\/2020\/07\/PR_Cepheid-2020-CID-RespiratoryXpert-MTB-XDR.pdf"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T17:33:54Z","timestamp":1600882434000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239328"}},"subtitle":[],"editor":[{"given":"Hasnain Seyed","family":"Ehtesham","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0239328","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]}}}